{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:40:17Z","timestamp":1760204417738,"version":"3.40.5"},"reference-count":47,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE:<\/jats:title>\n                  <jats:p>The uptake of new antipsychotic medications among children has not been studied adequately. Although ziprasidone received Food and Drug Administration approval for the treatment of psychotic disorders among children in June 2009, it first became available for off-label use by children in 2001 and presented an excellent case study for off-label market entry. The objective of this study was to determine the pattern of initiation and switching for off-label use of ziprasidone among Michigan children who were insured by Medicaid in the first year that ziprasidone was available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>We conducted a retrospective study by using Michigan Medicaid data for patients who were aged &amp;lt;21 years and had 2 years of continuous enrollment and at least 1 prescription for ziprasidone in the first year the medication was available. The main outcome measures were proportion of children prescribed ziprasidone as their first antipsychotic, with evidence of treatment resistance, and by a psychiatrist.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>In the first year, 292 individuals who met criteria were prescribed ziprasidone. Approximately 53% had a diagnosis of psychosis. Explosive personality disorder and oppositional defiant disorder were the next most common diagnoses. For 33% of individuals, this was the first antipsychotic medication. Only 12% of individuals showed evidence of treatment resistance to other antipsychotic medications before switching to ziprasidone.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>During the period when ziprasidone had no approved pediatric usages, a small percentage of patients who were prescribed ziprasidone showed evidence of treatment resistance, the primary expected indication. Some prescribing for ziprasidone in the first year in this population could be considered inappropriate considering what was known about the safety and efficacy of ziprasidone in children and adolescents at the time. \u201cFail first\u201d and prior authorization policies may be appropriate in the first year a medication is available so as to protect children from potential serious harm.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2009-1288","type":"journal-article","created":{"date-parts":[[2010,2,9]],"date-time":"2010-02-09T01:25:17Z","timestamp":1265678717000},"page":"475-482","source":"Crossref","is-referenced-by-count":12,"title":["Pediatric Uptake of a Newly Available Antipsychotic Medication"],"prefix":"10.1542","volume":"125","author":[{"given":"Robert B.","family":"Penfold","sequence":"first","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly J.","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Center for Innovation in Pediatric Practice and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Innovation in Pediatric Practice and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Strange","sequence":"additional","affiliation":[{"name":"Division of Child Psychiatry, Nationwide Children's Hospital, Columbus, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Pajer","sequence":"additional","affiliation":[{"name":"Center for Biobehavioral Health, Research Institute, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"issue":"10","key":"2021120905404959900_B1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1176\/ps.2008.59.10.1162","article-title":"Changing trends in pediatric antipsychotic use in Florida's Medicaid program","volume":"59","author":"Constantine","year":"2008","journal-title":"Psychiatr Serv"},{"issue":"2","key":"2021120905404959900_B2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ambp.2005.11.002","article-title":"Trends in prescribing of antipsychotic medications for US children","volume":"6","author":"Cooper","year":"2006","journal-title":"Ambul Pediatr"},{"issue":"5","key":"2021120905404959900_B3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1176\/ps.2008.59.5.507","article-title":"Who are the new users of antipsychotic medications","volume":"59","author":"Domino","year":"2008","journal-title":"Psychiatr Serv"},{"issue":"6","key":"2021120905404959900_B4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"2021120905404959900_B5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.chi.0000157543.74509.c8","article-title":"Trends in the use of typical and atypical antipsychotics in children and adolescents","volume":"44","author":"Patel","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"2021120905404959900_B6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/104454602760386905","article-title":"Trends in antipsychotic use in a Texas Medicaid population of children and adolescents: 1996 to 2000","volume":"12","author":"Patel","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"2021120905404959900_B7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1176\/appi.ps.57.1.63","article-title":"Trends in the use of psychotropic medications among adolescents, 1994 to 2001","volume":"57","author":"Thomas","year":"2006","journal-title":"Psychiatr Serv"},{"issue":"4","key":"2021120905404959900_B8","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1185\/030079902125000589","article-title":"Switching antipsychotic medications: general recommendations and switching to amisulpride","volume":"18","author":"Burns","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"2021120905404959900_B9","first-page":"4","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"2021120905404959900_B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1741-7015-6-17","article-title":"Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study","volume":"6","author":"Ganguli","year":"2008","journal-title":"BMC Med"},{"issue":"4","key":"2021120905404959900_B11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"2021120905404959900_B12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"3","key":"2021120905404959900_B13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/08039480510027689","article-title":"Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss","volume":"59","author":"Andersen","year":"2005","journal-title":"Nord J Psychiatry"},{"issue":"6","key":"2021120905404959900_B14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v66n0613","article-title":"Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole","volume":"66","author":"Brown","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"2021120905404959900_B15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4088\/JCP.v61n1105","article-title":"Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine","volume":"61","author":"Kinon","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2021120905404959900_B16","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1345\/aph.1H240","article-title":"Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances","volume":"40","author":"Chavez","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"1","key":"2021120905404959900_B17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10597-008-9154-7","article-title":"A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic","volume":"45","author":"Bastiaens","year":"2009","journal-title":"Community Ment Health J"},{"issue":"2","key":"2021120905404959900_B18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00213-007-0872-2","article-title":"How effective is it to sequentially switch among olanzapine, quetiapine and risperidone","volume":"195","author":"Suzuki","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"2021120905404959900_B19","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1093\/ajhp\/59.suppl_8.S22","article-title":"Rationale and strategies for switching antipsychotics","volume":"59","author":"Ganguli","year":"2002","journal-title":"Am J Health Syst Pharm"},{"key":"2021120905404959900_B20","first-page":"10","article-title":"Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes","volume":"68","author":"Lambert","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"2021120905404959900_B21","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/chi.0b013e3181570d9e","article-title":"Psychopharmacological treatment for very young children: contexts and guidelines","volume":"46","author":"Gleason","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"2021120905404959900_B22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/01.jcp.0000219917.88810.55","article-title":"Why do physicians switch from one antipsychotic agent to another? The \u201cphysician drug stereotype.\u201d","volume":"26","author":"Linden","year":"2006","journal-title":"J Clin Psychopharmacol"},{"issue":"2\u20133","key":"2021120905404959900_B23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0920-9964(01)00309-7","article-title":"Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study","volume":"57","author":"Voruganti","year":"2002","journal-title":"Schizophr Res"},{"issue":"6","key":"2021120905404959900_B24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/01.chi.0000215347.93902.3e","article-title":"Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents","volume":"45","author":"Sallee","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"2021120905404959900_B25","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2165\/00128072-200103120-00005","article-title":"Tolerability profile of atypical antipsychotics in children and adolescents","volume":"3","author":"Stigler","year":"2001","journal-title":"Paediatr Drugs"},{"key":"2021120905404959900_B26","first-page":"S254","article-title":"Impact of atypical antipsychotics on outcomes of care in schizophrenia","volume":"11","author":"Joyce","year":"2005","journal-title":"Am J Manag Care"},{"issue":"2\u20133","key":"2021120905404959900_B27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2003.07.009","article-title":"Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia","volume":"66","author":"Harvey","year":"2004","journal-title":"Schizophr Res"},{"issue":"5","key":"2021120905404959900_B28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1017\/S1092852900009342","article-title":"Improvement in prosocial functioning after a switch to ziprasidone treatment","volume":"9","author":"Loebel","year":"2004","journal-title":"CNS Spectr"},{"issue":"5","key":"2021120905404959900_B29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4088\/JCP.v64n0514","article-title":"Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia","volume":"64","author":"Weiden","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"2021120905404959900_B30","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1017\/S1092852900017004","article-title":"Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia","volume":"13","author":"Simpson","year":"2008","journal-title":"CNS Spectr"},{"key":"2021120905404959900_B31","unstructured":"Michigan Pharmaceutical Product List. Available at: www.michigan.fhsc.com\/Downloads\/MPPL20081101a.xls. Accessed July 18, 2009"},{"issue":"1","key":"2021120905404959900_B32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/schbul\/22.1.15","article-title":"Clozapine eligibility among state hospital patients","volume":"22","author":"Essock","year":"1996","journal-title":"Schizophr Bull"},{"key":"2021120905404959900_B33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1192\/bjp.170.6.507","article-title":"An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia","volume":"170","author":"Turetz","year":"1997","journal-title":"Br J Psychiatry"},{"issue":"7","key":"2021120905404959900_B34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1001\/archpsyc.63.7.721","article-title":"Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison","volume":"63","author":"Shaw","year":"2006","journal-title":"Arch Gen Psychiatry"},{"issue":"9","key":"2021120905404959900_B35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.4088\/JCP.v68n0902","article-title":"Ziprasidone in treatment-resistant schizophrenia: a 52-week, open label continuation study","volume":"68","author":"Loebel","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"2021120905404959900_B36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","article-title":"Clozapine and \u201chigh dose\u201d olanzapine in refractory early-onset schizophrenia: a 12 week randomized and double-blind comparison","volume":"63","author":"Kumra","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2021120905404959900_B37","unstructured":"Michigan Department of Community Health. Health Care Programs Eligibility. Available at: www.michigan.gov\/mdch\/0,1607,7-132-2943_4860-35199-00.html. Accessed April 29, 2009"},{"issue":"8","key":"2021120905404959900_B38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1176\/appi.ps.52.8.1081","article-title":"Prescription of psychotropic medications to youths in office-based practice","volume":"52","author":"Goodwin","year":"2001","journal-title":"Psychiatr Serv"},{"issue":"13","key":"2021120905404959900_B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/pn.44.13.0001","article-title":"FDA advisors back additional antipsychotics for use in teens","volume":"44","author":"Yan","year":"2009","journal-title":"Psychiatr News"},{"issue":"3","key":"2021120905404959900_B40","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment in children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"2021120905404959900_B41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.chi.0000145372.61239.bb","article-title":"Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study","volume":"44","author":"Blair","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"2021120905404959900_B42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1527-3458.2007.00008.x","article-title":"Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials","volume":"13","author":"Greenberg","year":"2007","journal-title":"CNS Drug Rev"},{"key":"2021120905404959900_B43","unstructured":"Verispan Inc. Personal Selling Audit, Hospital personal selling audit, Physician Meetings and Event Audit. Data available at: www.sdihealth.com. Accessed December 24, 2009"},{"issue":"7","key":"2021120905404959900_B44","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1176\/ps.2007.58.7.983","article-title":"Adding or switching antipsychotic medications in treatment refractory schizophrenia","volume":"58","author":"Kreyenbuhl","year":"2007","journal-title":"Psychiatr Serv"},{"issue":"2","key":"2021120905404959900_B45","first-page":"CD004397","article-title":"Pharmaceutical policies: effects on rational drug use, an overview of 13 reviews","author":"Aaserud","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2021120905404959900_B46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1377\/hlthaff.23.1.135","article-title":"Benefits and risks of increasing restrictions on access to costly drugs in Medicaid","volume":"23","author":"Soumerai","year":"2004","journal-title":"Health Aff (Millwood)"},{"issue":"4","key":"2021120905404959900_B47","first-page":"220","article-title":"Focus on ziprasidone: a review of its use in child and adolescent psychiatry","volume":"17","author":"Elbe","year":"2008","journal-title":"J Can Acad Child Adolesc Psychiatry"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/125\/3\/475\/894643\/zpe00310000475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/125\/3\/475\/894643\/zpe00310000475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T23:16:30Z","timestamp":1639091790000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/125\/3\/475\/72639\/Pediatric-Uptake-of-a-Newly-Available"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":47,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,3,1]]},"published-print":{"date-parts":[[2010,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2009-1288","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2010,3,1]]}}}